Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Figure 3 | BMC Cell Biology

Figure 3

From: A regulator of G Protein signaling, RGS3, inhibits gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone (LH) secretion

Figure 3

RGS3 inhibits GnRH-stimulated LH secretion. Rat anterior pituitary cells were infected or not with adeno-βgal or adeno-RGS3, and 72 h later treated with GnRH to stimulate LH secretion. Upper panel: Adeno-βgal infection was used to determine the fraction of total pituitary cells infected at each dose of adenovirus. Cell viability was measured as trypan blue exclusion. Middle panel: Adeno-βgal infection at various doses was used to control for the effect of RGS3 on GnRH-stimulated LH secretion. No dose of adeno-βgal had an effect on LH release (p < 0.05). Bottom panel: Dose-response relationship between dose of adeno-RGS3 and GnRH-stimulated LH secretion. Adeno-RGS3 doses of 0.2 M.O.I. and higher significantly inhibited LH release (p < 0.05); doses of 2.0 and 5.0 M.O.I, suppressed LH secretion to levels that were not significantly different from their cohorts not treated with GnRH (p < 0.05). Data are mean ± SEM of three independent experiments.

Back to article page